NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression- free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically sig. ...

Core Insights - Pfizer Inc. announced positive results from Cohort 3 of the BREAKWATER trial, which evaluates the efficacy of BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFIRI in patients with untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation [1] Group 1 - The BREAKWATER trial is pivotal for assessing the BRAFTOVI combination regimen [1] - The study focuses on patients with previously untreated metastatic colorectal cancer [1] - The combination includes BRAFTOVI, cetuximab (marketed as ERBITUX®), and FOLFIRI (fluorouracil, leucovorin, and irinotecan) [1]

After President Trump talked up leucovorin as a possible treatment for autism, demand for the FRAT blood test spiked https://t.co/KWixEVgvEV ...

All right, welcome back everybody. Luccoin is a generic drug derived from folic acid and currently approved for easing the side effects of chemotherapy in some patients. But after President Trump and HHS Secretary Robert F.Kennedy Jr. . announced a push to approve the drug for cerebral folate deficiency, that's a condition that often co-occurs with the ocism spectrum disorder that led the way for many new patients to seek out the medication. Joining us right now is an author of one study of luccoin conducte ...

The US Food and Drug Administration said it will approve the use of cancer drug leucovorin for a condition seen in some people with autism. Here's what to know https://t.co/BFOvL9Xe3e ...

Core Viewpoint - The heads of key health agencies are advocating for a focus on leucovorin, while Kennedy emphasizes the importance of raising awareness about the risks associated with acetaminophen [1] Group 1 - Key health agency leaders support prioritizing leucovorin in health discussions [1] - Kennedy feels a moral obligation to inform the public about acetaminophen risks [1]

Healthcare & Pharmaceutical Industry - Trump is promoting leucovorin as a possible autism treatment [1] - Medical professionals caution that leucovorin's effectiveness for autism may be exaggerated [1] - Further investigation is necessary to ascertain the true benefits of leucovorin for autism [1]

Healthcare Industry Focus - The Trump administration is promoting leucovorin as a possible autism treatment [1] - Medical professionals caution that leucovorin's advantages may be exaggerated and that further investigation is required [1]

Drug Information - FDA 将批准 leucovorin 这种癌症药物用于治疗自闭症 [1]

Group 1: Company Impact - Shares of Tylenol manufacturer Kenvue fell by 5.5% on the trading day following the announcement, marking a total decline of 17% in September due to the administration's potential link of the drug to autism [8] - Kenvue, which was spun off from Johnson & Johnson in 2023, stated that independent science shows no causal link between acetaminophen and autism, expressing concern over the health risks posed to expecting mothers by such claims [11] Group 2: Industry Context - The U.S. autism diagnosis rate has significantly increased, with the rate for 8-year-olds reaching 1 in 36 (2.77%) by 2020, up from 2.27% in 2018 and 0.66% in 2000, raising public concern [12] - Experts attribute the rise in autism diagnoses to improved screening methods and broader definitions of the condition, which have led to the identification of individuals with milder symptoms [14]